申请人:Samumed, LLC
公开号:US20190263821A1
公开(公告)日:2019-08-29
Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.
披露了用于治疗各种疾病和病理的吲唑化合物。更具体地说,本公开涉及使用吲唑化合物或其类似物来治疗由Wnt途径信号激活所特征的疾病(例如肌腱病、皮炎、牛皮癣、硬皮病、鱼鳞病、雷诺综合症、达里氏病、硬皮病、癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺病和骨关节炎),以及通过Wnt途径信号介导的细胞事件的调节,以及与DYRK1A过度表达相关的神经病理状况/疾病。